Progesterone conjugate - Levolta Pharmaceuticals

Drug Profile

Progesterone conjugate - Levolta Pharmaceuticals

Alternative Names: VOLT-02

Latest Information Update: 24 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Levolta Pharmaceuticals
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries; Female genital diseases; Menstruation disorders

Most Recent Events

  • 24 Mar 2017 Phase-II development for Brain injuries, Gynaecological disorders, and Menstruation disorders is ongoing in USA
  • 03 Nov 2014 Phase-II clinical trials in Brain injuries in USA (Parenteral)
  • 03 Nov 2014 Phase-II clinical trials in Gynaecological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top